Yusuf Erkul

Yusuf Erkul

Company: Kernal Biologics

Job title: CEO

Bio:

Seminar: Onco-Selective mRNA Therapeutics for Cancer Immunotherapy

  • Cancer ribosomes present unique opportunity for novel, onco-selective mRNA designs
  • Onco-selective mRNAs encoding immunogenic cell death proteins results in highly effective oncolytic activity in vitro
  • Onco-selective KR-333 mRNA LNPs enable robust antiactivity in syngeneic tumor models

Day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.